Table.
Brief medical and oncologic information of patients
| Patient ID | Medical comorbidities | Areas of unresectable disease | Initial CA-125 expression | No. of cycles of chemotherapy | Imaging modality used | Response to imaging at conclusion of chemotherapy | No. of cycles of olaparib | Current disease statusa |
|---|---|---|---|---|---|---|---|---|
| Patient A | Stroke | Upper abdomen, small bowel mesentery | 5655 | 9 | CT with contrast | cCR | 14 | NED |
| Patient B | — | Extensive lymphadenopathy including supraclavicular and mediastinal involvement | 362 | 6 | PET | cCR | 10 | NED |
CA-125, cancer antigen 125; cCR, complete clinical response; CT, computed tomography; NED, no evidence of disease; PET, positron emission tomography.
Vetter. Chemotherapy followed by PARP inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer during COVID-19. Am J Obstet Gynecol 2020.
a
Based on examination, imaging, and CA-125 testing.